A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC)
Status:
Terminated
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate if a maximum dose of 100 mg of dasatinib with
concurrent chemoradiation can be tolerated in patients with chemotherapy naive stage III
NSCLC in separate cohorts of locally advanced and potentially resectable disease.
Phase:
Phase 1
Details
Lead Sponsor:
Brown University
Collaborators:
Memorial Hospital of Rhode Island Rhode Island Hospital